A monofunctional Pt(II) complex combats triple negative breast cancer by triggering lysosome-dependent cell death.
Xiaomin ShenYue PengZidong YangRenhao LiHaixia ZhouXiaoxia YeZhong HanXiangchao ShiPublished in: Dalton transactions (Cambridge, England : 2003) (2024)
Monofunctional Pt(II) complexes with potent efficacy to overcome the drawbacks of current platinum drugs represent a promising therapeutic approach for triple negative breast cancer (TNBC). A heterocyclic-ligated monofunctional Pt(II) complex PtL with a unique action of mode was designed and investigated. PtL induced DNA single-strand breaks and caused genomic instability in TNBC cells. Mechanism studies demonstrated that PtL disrupted lysosomal acidity and function, which in turn triggered lysosome-dependent cell death. Furthermore, PtL showed convincing suppression in the tube forming and cell migratory abilities against the metastatic potential of TNBC cells. The synthesis and investigation of PtL revealed its potential value as an anti-TNBC drug and extended the family of monofunctional Pt(II) complexes.
Keyphrases
- cell death
- cell cycle arrest
- induced apoptosis
- fluorescent probe
- living cells
- single cell
- squamous cell carcinoma
- small cell lung cancer
- emergency department
- gene expression
- stem cells
- endoplasmic reticulum stress
- oxidative stress
- copy number
- mesenchymal stem cells
- high glucose
- single molecule
- diabetic rats
- cell free
- high resolution
- dna methylation
- risk assessment
- endothelial cells
- mass spectrometry
- quantum dots
- case control
- human health
- high speed